Published in Am J Cardiol on August 15, 2006
Cardiac Function in Patients With Hereditary Hemochromatosis | NCT00068159
Left ventricular long-axis function in treated haemochromatosis. Int J Cardiovasc Imaging (2008) 1.45
Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol (2010) 1.11
Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? Echocardiography (2009) 0.95
EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm (2016) 0.94
Does left atrial volume affect exercise capacity of heart transplant recipients? J Cardiothorac Surg (2010) 0.92
Augmentation of left atrial contractile function: a herald of iron overload in patients with beta thalassemia major. Pediatr Cardiol (2010) 0.78
High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease. Front Aging Neurosci (2013) 0.78
Hereditary hemochromatosis: a literature review and case report. Physiother Can (2010) 0.75
Iron Overload or Oxidative Stress? Insight into a Mechanism of Early Cardiac Manifestations of Asymptomatic Hereditary Hemochromatosis Subjects with C282Y Homozygosity. J Cardiovasc Transl Res (2016) 0.75
Assessment of left atrial ejection force in mildly asphyxiated newborns. Iran J Pediatr (2012) 0.75
Clinical significance of left atrial volume in clinical outcomes of heart transplant recipients. J Cardiothorac Surg (2015) 0.75
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med (2003) 13.84
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med (2003) 8.95
Prognostic value of coronary vascular endothelial dysfunction. Circulation (2002) 7.68
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med (2007) 5.18
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr (2004) 4.51
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation (2002) 3.09
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2004) 2.65
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2013) 2.17
Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am (2007) 2.17
Technology preview: X-ray fused with magnetic resonance during invasive cardiovascular procedures. Catheter Cardiovasc Interv (2007) 2.12
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion (2003) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98
Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation (2003) 1.98
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood (2009) 1.96
Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics (2002) 1.92
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant (2008) 1.83
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy (2009) 1.73
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Aortic dilatation and dissection in Turner syndrome. Circulation (2007) 1.65
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol (2005) 1.58
Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome. Transfusion (2013) 1.53
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation (2002) 1.53
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood (2012) 1.51
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion (2003) 1.45
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med (2011) 1.45
Growth hormone treatment and left ventricular dimensions in Turner syndrome. J Pediatr (2007) 1.44
Pediatric Fabry disease. Pediatrics (2005) 1.43
The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant (2008) 1.42
Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant (2008) 1.41
Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol (2005) 1.41
Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood (2009) 1.40
Summary of the key features of seven biomathematical models of human fatigue and performance. Aviat Space Environ Med (2004) 1.39
The value of pH as a quality control indicator for apheresis platelets. Transfusion (2005) 1.38
Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol (2002) 1.36
Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol (2006) 1.34
Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol (2008) 1.34
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol (2008) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Increased pulmonary pressures and myocardial wall stress in children with severe malaria. J Infect Dis (2010) 1.33
Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood (2002) 1.32
Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol (2012) 1.31
G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion (2003) 1.29
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood (2008) 1.28
Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood (2002) 1.27
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol (2002) 1.24
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
Iron replacement therapy in the routine management of blood donors. Transfusion (2011) 1.20
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol (2008) 1.15
Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem (2003) 1.15
Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol (2006) 1.14
Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion (2002) 1.13
Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration. Transfusion (2004) 1.12
Coronary artery anomalies and variants: technical feasibility of assessment with coronary MR angiography at 3 T. Radiology (2008) 1.12
Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes (2006) 1.11
Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol (2010) 1.11
Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors. PLoS Negl Trop Dis (2013) 1.11
Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion (2008) 1.11
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage (2010) 1.09
The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion (2007) 1.09
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain (2009) 1.08